138 related articles for article (PubMed ID: 36572639)
41. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
[TBL] [Abstract][Full Text] [Related]
42. The application of tandem aza-wittig reaction to synthesize artemisinin-guanidine hybrids and their anti-tumor activity.
Xie L; Zhao Y; Zhai X; Li P; Liu C; Li Y; Gong P
Arch Pharm (Weinheim); 2011 Oct; 344(10):631-8. PubMed ID: 21984013
[TBL] [Abstract][Full Text] [Related]
43. Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
Buragohain P; Saikia B; Surineni N; Barua NC; Saxena AK; Suri N
Bioorg Med Chem Lett; 2014 Jan; 24(1):237-9. PubMed ID: 24332623
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and cytotoxic activity of new artemisinin hybrid molecules against human leukemia cells.
Letis AS; Seo EJ; Nikolaropoulos SS; Efferth T; Giannis A; Fousteris MA
Bioorg Med Chem; 2017 Jul; 25(13):3357-3367. PubMed ID: 28456567
[TBL] [Abstract][Full Text] [Related]
45. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.
Ke S; Shi L; Yang Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4628-31. PubMed ID: 26320625
[TBL] [Abstract][Full Text] [Related]
46. The anti-breast cancer potential of dihydroartemisinin-isatin hybrids with hydrogen bond donors at C-3 position of isatin moiety.
Ding F; Chen X; Cao W; Dong T; Wang P
Fitoterapia; 2023 Mar; 165():105426. PubMed ID: 36608710
[TBL] [Abstract][Full Text] [Related]
47. Discovery of novel dihydroartemisinin-cinnamic hybrids inducing lung cancer cells apoptosis via inhibition of Akt/Bad signal pathway.
Hu Y; Wang Y; Li N; Chen L; Sun J
Bioorg Chem; 2021 Jun; 111():104903. PubMed ID: 33894433
[TBL] [Abstract][Full Text] [Related]
48. Anti-tumor activity of new artemisinin-chalcone hybrids.
Xie L; Zhai X; Liu C; Li P; Li Y; Guo G; Gong P
Arch Pharm (Weinheim); 2011 Oct; 344(10):639-47. PubMed ID: 21984014
[TBL] [Abstract][Full Text] [Related]
49. Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.
Eldehna WM; Salem R; Elsayed ZM; Al-Warhi T; Knany HR; Ayyad RR; Traiki TB; Abdulla MH; Ahmad R; Abdel-Aziz HA; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1424-1435. PubMed ID: 34176414
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
Wang J; Yun D; Yao J; Fu W; Huang F; Chen L; Wei T; Yu C; Xu H; Zhou X; Huang Y; Wu J; Qiu P; Li W
Eur J Med Chem; 2018 Jan; 144():493-503. PubMed ID: 29288946
[TBL] [Abstract][Full Text] [Related]
51. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
52. Synthesis, biological evaluation and preliminary mechanisms of 6-amino substituted harmine derivatives as potential antitumor agents.
Hu D; Han G; Ren H; Li X; Li X; Yue L; Xu J; Feng J; Guo L
Fitoterapia; 2022 Nov; 163():105329. PubMed ID: 36209955
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.
Zhang N; Yu Z; Yang X; Hu P; He Y
Eur J Med Chem; 2018 Apr; 150():829-840. PubMed ID: 29597166
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
[TBL] [Abstract][Full Text] [Related]
55.
Hallaq T; Al-Hiari Y; Kasabri V; AlBashiti R; AlAlawi S; Telfah A
Anticancer Agents Med Chem; 2022; 22(19):3304-3321. PubMed ID: 35570520
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, biological activity evaluation and mechanism of action of novel bis-isatin derivatives as potential anti-liver cancer agents.
Li Z; Ma J; Tian M; Xia P; Lv X; Hou R; Jiang Y; Xu X; Jia Z; Wang J; Li Z
Bioorg Med Chem Lett; 2024 Feb; 99():129613. PubMed ID: 38224754
[TBL] [Abstract][Full Text] [Related]
57. Design and synthesis of thiadiazolo-carboxamide bridged β-carboline-indole hybrids: DNA intercalative topo-IIα inhibition with promising antiproliferative activity.
Tokala R; Sana S; Lakshmi UJ; Sankarana P; Sigalapalli DK; Gadewal N; Kode J; Shankaraiah N
Bioorg Chem; 2020 Dec; 105():104357. PubMed ID: 33091673
[TBL] [Abstract][Full Text] [Related]
58. Mono- and bis-pyrazolophthalazines: Design, synthesis, cytotoxic activity, DNA/HSA binding and molecular docking studies.
Hamidinasab M; Ameri A; Hekmat A; Forootanfar H; Mortezazadeh T; Bodaghifard MA; Peytam F; Esmaeili R; Foroumadi A; Sharifzadeh M; Mobinikhaledi A; Khoobi M
Bioorg Med Chem; 2021 Jan; 30():115944. PubMed ID: 33352388
[TBL] [Abstract][Full Text] [Related]
59. Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents.
Ricci J; Kim M; Chung WY; Park KK; Jung M
Chem Pharm Bull (Tokyo); 2011; 59(12):1471-5. PubMed ID: 22130368
[TBL] [Abstract][Full Text] [Related]
60. Hybrids of 4-hydroxy derivatives of goniothalamin and piplartine bearing a diester or a 1,2,3-triazole linker as antiproliferative agents.
Grigolo TA; Braga CB; Ornelas C; Russowsky D; Ferreira-Silva GA; Ionta M; Pilli RA
Bioorg Chem; 2021 Nov; 116():105292. PubMed ID: 34509797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
